UnknownNot applicableNCT02089828
Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia
Studying Buerger disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shanghai Zhongshan Hospital
- Principal Investigator
- Weiguo Fu, M.D.Fudan University
- Intervention
- autologous purified CD34+ cells(other)
- Enrollment
- 50 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2014 – 2018
Study locations (1)
- Zhihui Dong, Shanghai, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02089828 on ClinicalTrials.govOther trials for Buerger disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07215923A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy SmokersAntidote Therapeutics, Inc
- ENROLLING BY INVITATIONNCT07023965Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)Beijing Northland Biotech. Co., Ltd.
- RECRUITINGPHASE4NCT05854615Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's DiseaseCell Biopeutics Resources Sdn Bhd